187 related articles for article (PubMed ID: 23934022)
21. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.
Westdorp H; Creemers JHA; van Oort IM; Schreibelt G; Gorris MAJ; Mehra N; Simons M; de Goede AL; van Rossum MM; Croockewit AJ; Figdor CG; Witjes JA; Aarntzen EHJG; Mus RDM; Brüning M; Petry K; Gotthardt M; Barentsz JO; de Vries IJM; Gerritsen WR
J Immunother Cancer; 2019 Nov; 7(1):302. PubMed ID: 31727154
[TBL] [Abstract][Full Text] [Related]
22. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL; Schiffman K; Cheever MA; Disis ML
Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
[TBL] [Abstract][Full Text] [Related]
23. Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients.
Reyes D; Salazar L; Espinoza E; Pereda C; Castellón E; Valdevenito R; Huidobro C; Inés Becker M; Lladser A; López MN; Salazar-Onfray F
Br J Cancer; 2013 Sep; 109(6):1488-97. PubMed ID: 23989944
[TBL] [Abstract][Full Text] [Related]
24. Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy.
Zahm CD; Johnson LE; McNeel DG
Cancer Immunol Immunother; 2019 Oct; 68(10):1661-1669. PubMed ID: 31606777
[TBL] [Abstract][Full Text] [Related]
25. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study.
Wiedermann U; Wiltschke C; Jasinska J; Kundi M; Zurbriggen R; Garner-Spitzer E; Bartsch R; Steger G; Pehamberger H; Scheiner O; Zielinski CC
Breast Cancer Res Treat; 2010 Feb; 119(3):673-83. PubMed ID: 20092022
[TBL] [Abstract][Full Text] [Related]
26. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Brown TA; Mittendorf EA; Hale DF; Myers JW; Peace KM; Jackson DO; Greene JM; Vreeland TJ; Clifton GT; Ardavanis A; Litton JK; Shumway NM; Symanowski J; Murray JL; Ponniah S; Anastasopoulou EA; Pistamaltzian NF; Baxevanis CN; Perez SA; Papamichail M; Peoples GE
Breast Cancer Res Treat; 2020 Jun; 181(2):391-401. PubMed ID: 32323103
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and antitumor activity of the superlytic λF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice.
Barati N; Razazan A; Nicastro J; Slavcev R; Arab A; Mosaffa F; Nikpoor AR; Badiee A; Jaafari MR; Behravan J
Cancer Lett; 2018 Jun; 424():109-116. PubMed ID: 29580807
[TBL] [Abstract][Full Text] [Related]
28. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
29. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
Disis ML; Wallace DR; Gooley TA; Dang Y; Slota M; Lu H; Coveler AL; Childs JS; Higgins DM; Fintak PA; dela Rosa C; Tietje K; Link J; Waisman J; Salazar LG
J Clin Oncol; 2009 Oct; 27(28):4685-92. PubMed ID: 19720923
[TBL] [Abstract][Full Text] [Related]
30. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.
Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG
J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736
[TBL] [Abstract][Full Text] [Related]
31. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
[TBL] [Abstract][Full Text] [Related]
32. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.
Becker JT; Olson BM; Johnson LE; Davies JG; Dunphy EJ; McNeel DG
J Immunother; 2010; 33(6):639-47. PubMed ID: 20551832
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154).
Perambakam S; Xie H; Edassery S; Peace DJ
Clin Dev Immunol; 2010; 2010():473453. PubMed ID: 21253471
[TBL] [Abstract][Full Text] [Related]
34. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
Noguchi M; Arai G; Egawa S; Ohyama C; Naito S; Matsumoto K; Uemura H; Nakagawa M; Nasu Y; Eto M; Suekane S; Sasada T; Shichijo S; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2020 May; 69(5):847-857. PubMed ID: 32025848
[TBL] [Abstract][Full Text] [Related]
35. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.
Chen G; Gupta R; Petrik S; Laiko M; Leatherman JM; Asquith JM; Daphtary MM; Garrett-Mayer E; Davidson NE; Hirt K; Berg M; Uram JN; Dauses T; Fetting J; Duus EM; Atay-Rosenthal S; Ye X; Wolff AC; Stearns V; Jaffee EM; Emens LA
Cancer Immunol Res; 2014 Oct; 2(10):949-61. PubMed ID: 25116755
[TBL] [Abstract][Full Text] [Related]
36. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer.
Eaton JD; Perry MJ; Nicholson S; Guckian M; Russell N; Whelan M; Kirby RS
BJU Int; 2002 Jan; 89(1):19-26. PubMed ID: 11849155
[TBL] [Abstract][Full Text] [Related]
38. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.
Knutson KL; Schiffman K; Disis ML
J Clin Invest; 2001 Feb; 107(4):477-84. PubMed ID: 11181647
[TBL] [Abstract][Full Text] [Related]
39. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
[TBL] [Abstract][Full Text] [Related]
40. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.
Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM
Front Immunol; 2018; 9():2145. PubMed ID: 30283461
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
